Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias

• Appearance of dyskinesia is a common problem of long-term Levodopa (L-DOPA) treatment in Parkinson's disease (PD) patients and represents a major limitation for the pharmacological management of the motor symptoms in the advanced stages of disease. An increasing body of evidence points to dopamine released as a false neurotransmitter from the striatal serotonin terminals as the main pre-synaptic determinant of L-DOPA-induced dyskinesia. Here we review the animal experimental and human clinical data in support of this view, which point to the serotonin system as a promising target for anti-dyskinetic therapy in PD patients under L-DOPA medication.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Neurosciences (hsv//eng)

Nyckelord

Animals

Clinical Trials as Topic

Dopamine

Dyskinesia, Drug-Induced

Humans

Levodopa

Parkinson Disease

Parkinsonian Disorders

Presynaptic Terminals

Protein Isoforms

Receptors, Dopamine

Receptors, Serotonin

Serotonin

Journal Article

Research Support, Non-U.S. Gov't

Review

Publikations- och innehållstyp

art (ämneskategori)

ref (ämneskategori)